Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report
As general background, a cell therapy company with one marketed product is valued on its sales ramp, gross margin and cash runway. Each quarter shows whether treatment centres are adding patients to AUCATZYL, an obecabtagene autoleucel therapy for adult B-cell acute lymphoblastic leukaemia. Guidance …
Key HighlightsKaryopharm Therapeutics (NASDAQ:KPTI) is indicated at USD 0.0311 pre-market on November 10, 2026, which is 22.25% below a calculated prior close of USD 0.0400.The company lodged Chapter 11 papers on November 2, 2026, supported by a USD 55 millionBankruptcyloan, with Ayrmid leading the …
Key HighlightsJin Medical International (NASDAQ:ZJYL) was indicated at USD 3.25 before Tuesday's open on November 10, 2026, 17.7% under a calculated prior close of USD 3.95, after Monday's rise of USD 0.59 or 17.6%.Based on Monday's close, the company'sMarket Valuestood at USD 30.92 million …
No catalyst for the move has been confirmed in published coverage. Relevant background: on September 16, 2026 the company flagged its first treated patient in an IDE study for the vCLAS Ultra system, which targets ventricular tachycardia, and around September 23, 2026 it announced …
No company release or filing dated November 9 or November 10, 2026 turned up in published coverage, so the cause of the decline is unknown. In general, nano-cap biotechs often move on a financing or at-the-market offering, a Nasdaq minimum bid price deficiency notice, …
Perinatal death counts were 2,744 in 2021, 2,739 in 2022 and 2,695 in 2023. They increased to 2,952 in 2024 before decreasing to 2,895 in 2025.
The published series records 745 neonatal deaths in 2021, 695 in 2022 and 660 in 2023. The count then increased to 719 in 2024 and 784 in 2025.
The national total comprised 2,111 stillbirths and 784 neonatal deaths. Stillbirths decreased by 122, or 5.5%, from 2,233 in 2024. Neonatal deaths increased by 65, or 9.0%, from 719.
Medibank reported AUD 6.9 billion in total claims paid in FY26, while delivering almost AUD 300 million of additional value to customers during the year. The company said it was balancing rising healthcare costs against affordability considerations for policyholders. Claims payments and customer benefits …
For FY26, nib reported total income of AUD 3,854.8 million, up 6.2% year on year. InsuranceRevenueincreased 6.5% to AUD 3,685.7 million. Group underlying operating profit increased 9.1% to AUD 260.9 million, supported by performance across several insurance operations and improved productivity.Underlying Profitis a management …
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…